Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (528 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: extensionlong termterm safetysafety tolerabilitythe long
  Phrases that lowered it: patientsvisitto evaluateevaluate theopen label
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.3% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports with a death: 28.2% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 285 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.5% (raises risk) · Drug's FDA history
• Minimum age: not given (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Sponsor's past trials: 301 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 1833 (lowers risk) · Drug's FDA history
• Maximum age: not given (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) NCT01117987 · started 2010 · scored riskier than 77% of active trials terminated
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan NCT02042014 · started 2014 · scored riskier than 76% of active trials completed
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients NCT02939599 · started 2018 · scored riskier than 99% of active trials terminated
• Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants NCT01392469 · started 2011 · scored riskier than 26% of active trials completed
• ACT-293987 in Pulmonary Arterial Hypertension NCT01112306 · started 2010 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.